Cancer Pharmacogenomics: Early Promise, But Concerted Effort Needed

The past decade has brought together substantial advances in human genome analysis and a maturation of understanding of tumor biology. Although there is much progress still to be made, there are now several prominent examples in which tumor-associated somatic mutations have been used to identify cel...

Full description

Saved in:
Bibliographic Details
Published in:Science (American Association for the Advancement of Science) 2013-03, Vol.339 (6127), p.1563-1566
Main Author: McLeod, Howard L.
Format: Article
Language:English
Subjects:
Antineoplastic Agents - administration & dosage
Antineoplastic Agents - adverse effects
Antineoplastic Agents - therapeutic use
Biology
Biomarkers, Pharmacological
Biomarkers, Tumor - genetics
Breast cancer
Cancer
Clinical trials
DNA
Dosing
Drug Design
Drugs
Female
Genetic Markers
Genetic mutation
Genome, Human
Genomics
Germ-Line Mutation
Humans
Molecular Targeted Therapy
Mutations
Neoplasms - drug therapy
Neoplasms - genetics
Oncology
Patients
Pharmaceutical sciences
Pharmacogenetics
REVIEWS
Sequencing
Side effects
Somatic mutation
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The past decade has brought together substantial advances in human genome analysis and a maturation of understanding of tumor biology. Although there is much progress still to be made, there are now several prominent examples in which tumor-associated somatic mutations have been used to identify cellular signaling pathways in tumors. This in turn has led to the development of targeted therapies, with somatic mutations serving as genomic predictors of tumor response and providing new leads for drug development. There is also a realization that germline DNA variants can help optimize cancer drug dosing and predict the susceptibility of patients to the adverse side effects of these drugs—knowledge that ultimately can be used to improve the benefit:risk ratio of cancer treatment for individual patients.
ISSN:0036-8075
1095-9203
DOI:10.1126/science.1234139